RPRX
$43.20
Royalty Pharma Plc Cl A
($.92)
(2.09%)
RPRX
Earnings Whisper ®
N/A
2nd Quarter June 2020
Consensus:  $0.61
Revenue:  N/A
Wednesday
Aug 12
8:45 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when RPRX reports earnings?
Beat
Meet
Miss

Where is RPRX's stock price going from here?
Up
Flat
Down
Stock chart of RPRX
Analysts
Summary of analysts' recommendations for RPRX
Score
Grade
Pivots
Resistance
$47.79
$46.56
$44.88

$43.65

Support
$41.97
$40.74
$39.06
Tweet
Growth
Description
Zonagen Inc. is a biopharmaceutical company engaged in the development of products for the human reproductive system, including sexual dysfunction, vaccine adjuvants, products for fertility and female health as well as urological applications, specifically prostate cancer. Zonagen's products to treat sexual dysfunction all incorporate phentolamine mesylate, an alpha-adrenergic blocker, as the active agent. Zonagen's lead product, VASOMAX(R), is a rapidly disintegrating oral formulation of phentolamine for the treatment of male erectile dysfunction.
Peers
BiogenAmgenGilead SciencesNeurocrine BiosciencesSeattle GeneticsBluebird BioQiagen N.V.NovavaxRepligenBio-Techne